The Office of Inspector General (“OIG”) recently issued advisory opinion 25‑12 (“the Opinion”), which addresses a home care agency’s plan to advertise and pay sign‑on bonuses to prospective attendant‑employees, many of whom are family members of Medicaid beneficiaries who would also select the agency for their relative’s Medicaid‑covered services.  OIG concluded that the arrangement presented an unacceptable risk under each of the federal Anti‑Kickback Statute (“AKS”) and the Beneficiary Inducements Civil Monetary Penalties Law (“CMPL”), providing a rare peek behind the employee safe harbor curtain.

The Proposal

The requestors operate a home care agency participating in a state Medicaid program that covers in‑home support services through waivers and other initiatives.  Eligible individuals can select attendants of their choice to provide personal care, homemaker services, and certain health maintenance activities.  The agency employs the attendants and bills Medicaid for services.  The agency stated that they expect attendants would primarily be family members who would also select the agency on the eligible‑individual’s behalf.

Under the proposal, the agency would publicly advertise employment opportunities to prospective attendants and offer a sign‑on bonus.  As explained by the requestor, the purpose of the sign‑on bonus was to entice prospective attendants to choose the agency over competitors.  Additionally, all attendants would be bona fide employees of the agency once hired.

OIG’s Analysis

OIG analyzed the proposal under the AKS and the Beneficiary Inducements CMPL and found it fell short under each law.

AKS Analysis.  OIG determined that the proposed sign‑on bonus offer and advertising would constitute an offer of “remuneration” implicating the AKS.  If undertaken with the requisite intent, OIG concluded that the proposal would be grounds for sanctions under the AKS.  Notably, while the AKS includes a statutory exception and safe harbor for bona fide employees, OIG determined that the proposal was not low enough risk to find protection under either the exception or the safe harbor.

Beneficiary Inducements CMPL Analysis.  OIG also concluded that the offer of a sign‑on bonus to a prospective attendant‑employee who would likely select an agency for a family member would likely influence that selection and, therefore, would be a prohibited offer of remuneration under the Beneficiary Inducements CMPL.  OIG determined that no exception applied, and the proposal was not low enough risk to find protection from a potential Beneficiary Inducements CMPL violation.

Why The Proposal Could Not Find Protection

Although sign‑on bonuses are common in employment contracting, OIG emphasized a unique, “inextricable link” warranting heightened scrutiny: the same person being recruited as an employee would also select the agency for Medicaid‑reimbursable services for a family member.  In OIG’s view, advertising a sign‑on bonus to such attendant‑employees operates as a solicitation for a referral before employment begins, rather than as compensation “for employment” within the employee exception or safe harbor.

OIG further highlighted steering, competition, and quality risks associated with the proposal.  Specifically, prospective attendant‑employees could interpret the advertised bonus as upfront cash, increasing the likelihood that they pick an agency based on the most compelling bonus rather than service quality—potentially diverting resources away from client care.  OIG also noted a possible “arms race” of escalating bonuses across agencies.  These factors elevated the risk of potential fraud and abuse beyond what OIG considered acceptable or low enough to provide a favorable advisory opinion.

Takeaways and Potential Risk Mitigation Considerations

The Opinion should stand as a reminder that the bona fide employment exception and safe harbor are not absolutely protective of certain arrangements if the requisite intent is potentially present.  In particular, here, OIG determined that the recruitment of a beneficiary’s selection agent as an employee was high enough risk because of the potential to generate improper referrals.

The Opinion also offers insight into what OIG views as material for its risk analysis:  publicly advertised sign‑on bonuses in government‑funded programs.  In light of this, organizations should consider reassessing their recruitment messaging, bonus structures, and any targeting that may overlap with or be related to beneficiary decisionmakers, including by, for example:

  • Implementing controls to separate caregiver recruitment from beneficiary selection processes.
  • Marketing based on service quality and clinical supervision (for example, the agency’s 24‑hour back‑up services or training program).
  • Ensuring appropriate supporting documentation for compensation paid in exchange for employment services.

Proskauer’s Health Care Group is closely monitoring developments in this area.  For more insights on health care law and policy, subscribe to Proskauer’s Health Care Law Brief below.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of G. Patrick Regan G. Patrick Regan

Pat Regan is an associate in Proskauer’s Litigation Department and a member of the Health Care Group. He focuses on representing clients in complex litigation, government investigations, and regulatory matters within the health care industry. Pat has handled cases involving the False Claims…

Pat Regan is an associate in Proskauer’s Litigation Department and a member of the Health Care Group. He focuses on representing clients in complex litigation, government investigations, and regulatory matters within the health care industry. Pat has handled cases involving the False Claims Act, the Anti-Kickback Statute, Section 1557 of the Affordable Care Act, Medicare Advantage, Medicaid, ERISA, “qui tam” whistleblower lawsuits, and payor-provider contract disputes. He has litigated at all levels of the federal court system and in arbitrations.

Before joining Proskauer, Pat worked at Williams & Connolly LLP. He also served as a judicial law clerk for Chief Judge Philip S. Gutierrez of the U.S. District Court for the Central District of California and Judge Sandra S. Ikuta of the U.S. Court of Appeals for the Ninth Circuit. In law school, Pat served as an articles editor for the California Law Review and as the student co-director for Berkeley Law’s first-year written and oral advocacy program.

Photo of Matthew J. Westbrook Matthew J. Westbrook

Matt Westbrook is a senior counsel in the Corporate Department and a member of the Health Care Group. His practice focuses on providing regulatory compliance advice for the Firm’s health care clients, including service providers, health plans, operators, investors, and lenders, among others.

Matt Westbrook is a senior counsel in the Corporate Department and a member of the Health Care Group. His practice focuses on providing regulatory compliance advice for the Firm’s health care clients, including service providers, health plans, operators, investors, and lenders, among others. Matt specifically provides advice on fraud and abuse matters arising under the Federal False Claims Act (FCA), Civil Monetary Penalties Law, Federal Anti-Kickback Statute (AKS), and Physician Self-Referral Law (Stark Law), as well as on the regulations promulgated by the Drug Enforcement Administration (DEA) and the Department of Health and Human Services, including the Office of Inspector General (OIG), Centers for Medicare & Medicaid Services (CMS), and Food and Drug Administration (FDA).

Before joining the Firm, Matt served as senior counsel in OIG’s Administrative and Civil Remedies Branch. At OIG, Matt was responsible for determining whether to impose administrative sanctions, including civil money penalties and Federal health care program exclusions, against health care providers and suppliers, and whether to impose civil money penalties on hospitals and physicians in connection with matters referred to CMS under the Emergency Medical Treatment and Labor Act (EMTALA). During his tenure, Matt also litigated exclusion appeals before administrative law judges and appellate panels of the Departmental Appeals Board; advised United States Attorney’s Offices on exclusions appealed to Federal district courts; resolved voluntary self-disclosures submitted by providers and grant and contract recipients; and participated in the negotiations and settlements of FCA matters by the Department of Justice involving the AKS, Stark Law, CMS reimbursement issues, and DEA and FDA compliance issues. In connection with certain FCA resolutions, Matt also negotiated and monitored corporate integrity agreements.

On the Florida junior circuit and in college, Matt was a competitive tennis player. Matt played on the varsity team and was captain his senior year at Rhodes College, earning ITA Division III and SCAC All-Academic Honor Roll awards his sophomore, junior, and senior years. Matt is an active member of the American Health Law Association (AHLA) and currently serves as a Vice Chair of AHLA’s Fraud and Abuse Practice Group.

Articles:

Matthew J. Westbrook and David M. Blank, “Using OIG’s Cross-Component Audit and Enforcement Data to Strengthen Your Compliance Program,” Compliance Today (February 2024).

Ed Kornreich, Matthew Westbrook, and Angela Gichinga, “Bracing for the Impact of the No Surprises Act,” Westlaw Today (June 16, 2022).

Presentations:

Bill Mathias and Matt Westbrook, “‘Lightning Round’:  A Fraud & Abuse Due Diligence Game Show,” American Health Law Association (Health Care Transactions Conference, May 5–6, 2025).

Matthew J. Westbrook and David M. Blank, “Recent Trends in CMPL Enforcement, American Health Law Association (Webinar, May 24, 2023).

Photo of Devin Cohen Devin Cohen

Devin Cohen is a partner in the Corporate Department and a member of Proskauer’s Health Care Group.

Devin counsels leading health care organizations and private equity sponsors operating at the cutting edge of the industry on their most important transactional and regulatory matters.

Devin Cohen is a partner in the Corporate Department and a member of Proskauer’s Health Care Group.

Devin counsels leading health care organizations and private equity sponsors operating at the cutting edge of the industry on their most important transactional and regulatory matters. He has a deep understanding of both deal mechanics and the evolving regulatory landscapes in the areas of strategic investment, vertical integration, insurance and brokerage, as well as research.

Over the course of his career, Devin has advised a wide range of health care organizations and investors on value-based care arrangements and initiatives, and routinely advises insurers and providers to structure collaborative care models and Medicare Advantage. In addition, Devin has worked with clients on matters related to pharmaceutical and medical device research and development and clinical trials, including fraud and abuse considerations, human subject protections requirements, animal welfare standards, sponsored and investigator-initiated research negotiations, and compliance monitoring.

Clients value Devin’s responsiveness, as well as his ability to cut through complexity to provide clear, actionable guidance. They also appreciate the strong people skills he brings to the table, which are particularly helpful in negotiations.

Devin’s passion for health care extends to his community service and pro bono efforts in the Boston area. He works with Heading Home and other non-profits providing shelter to those in need throughout the Commonwealth of Massachusetts, among others.

Devin joins Proskauer from Ropes & Gray LLP where he was a partner in the firm’s Health Care practice.

Experience

Devin regularly works with a wide range of health care organizations — including physician groups, academic medical centers, clinical networks, hospitals, dental and management services organizations, insurers, brokers/agents, pharmaceutical and medical device manufacturers, and provider organizations — as well as industry investors, across areas such as:

Health care transactions and investments

  • Provide transactional and regulatory counsel to providers and investors. Examples include:
  • Assisted multiple regional health plans in their mergers and acquisitions of new plans to expand insurance product offerings.
  • Advised a private equity firm on its investment in an online insurance brokerage platform.
  • Counsel investors on emerging state health care transaction laws, corporate practice of medicine, and MSO/DSO structuring.
  • Advise multiple private sponsors on CRO and SMO investments

Value-based care arrangements

  • Counsel a wide range of providers, payors, practice management organizations, vendors and industry investors in the areas of Medicare Advantage, CMMI program participation, state risk-bearing implications and insurance requirements.
  • Advise on strategic partnerships and joint ventures, including innovative collaborations aimed at expanding access to value-based primary care for Medicare beneficiaries.

Regulatory and compliance

  • Routinely counsel Medicare Advantage Organizations, FDRs and program vendors on Medicare Advantage regulatory and contracting standards.
  • Advise investors and brokers/agencies on emerging Medicare requirements, including emerging standards related to sales commissions payments.
  • Advise medical device and pharmaceutical manufacturers on regulatory standards related to customer and patient interactions, marketing and clinician education standards, industry and jointly sponsored CME, patient assistance programs, and related compliance program requirements.

Clinical research and related activities

  • Regularly provide guidance on drug and drug component development/commercialization considerations for sites, investigators and sponsors.
  • Routinely advise institutional and start-up manufacturers, as well as CROs and trial sites, on cutting-edge clinical trial contracting negotiations.
  • Provide counsel on research affiliation agreements, including advising a large academic medical center on developing and implementing its research affiliation agreement with a local pediatric health network.
  • Conduct regulatory diligence for private equity clients regarding their planned investments in companies that participate in the clinical research enterprise.
  • Advise academic medical centers on research misconduct matters.